Lercanidipina Zentiva (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells. This blockade reduces calcium entry during muscle contraction, leading to relaxation of arterial smooth muscle, vasodilation, and a subsequent decrease in peripheral resistance. The resulting effect is a reduction in systolic and diastolic blood pressure.

The appropriate dose of Lercanidipina Zentiva is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. The prescriber will select the starting dose and any subsequent adjustments according to clinical response and tolerability.

Safety data for lercanidipine in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure by vasodilation. Lercanidipine is more lipophilic, which may result in a slower onset and longer duration of action, while amlodipine is known for its once‑daily dosing and extensive clinical experience. Choice between them depends on individual patient response, tolerability, and physician preference.

Store tablets at below 25 °C (77 °F) in the original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in bathrooms or near kitchen appliances. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

Lercanidipina Zentiva is taken orally, usually once daily. Swallow the tablet whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional. Dosing time can be consistent each day, preferably in the morning or as directed by the prescriber.

The most serious adverse events include severe hypotension (dangerously low blood pressure), angioedema (rapid swelling of the face, lips, tongue, or throat that may compromise breathing), and hepatic dysfunction (elevated liver enzymes or jaundice). Patients should seek immediate medical attention if they experience fainting, swelling of the airway, or signs of liver injury such as dark urine or yellowing of the skin.

Lercanidipina Zentiva is contraindicated in patients with known hypersensitivity to lercanidipine or any excipients, those with severe aortic stenosis, uncontrolled hypotension (systolic blood pressure < 90 mmHg), and individuals taking strong CYP3A4 inhibitors such as ketoconazole or clarithromycin without appropriate dose adjustment. Clinicians should also exercise caution in patients with significant hepatic impairment.